Skip to main content
Erschienen in: Rheumatology International 12/2012

01.12.2012 | Original Article

Investigation of the change in CD4+ T cell subset in children with Henoch–Schonlein purpura

verfasst von: Yuan-yuan Li, Cheng-rong Li, Guo-bing Wang, Jun Yang, Ying Zu

Erschienen in: Rheumatology International | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Helper T (Th) cells comprising Th1, Th2, Th17, and Treg are involved in the pathogenesis of various vascular inflammations, and information about Th cells in Henoch–Schonlein purpura (HSP) is still controversial. The aim of our study was to investigate the changes in CD4+ T cell subsets and their roles in the pathogenesis of HSP. Thirty children with diagnosis of HSP and thirty age-matched healthy controls were enrolled in this study. Real-time PCR was used to evaluate the mRNA expression levels of transcriptional factors and cytokines of CD4+ T cells. Proportions of Th1, Th2, Th17, and Treg cells in peripheral blood were detected by flow cytometry. Plasma cytokine concentrations were measured by ELISA. The proportions of Th2 and Th17 cells increased significantly in children with acute HSP (P < 0.05), while there were no significant differences between HSP and healthy controls regarding the proportions of Treg cells and Th1 cells (P > 0.05). mRNA levels of transcriptional factors and cytokines of Th2 and Th17 cells were significantly up-regulated (P < 0.05), while the differences were not significant as to those of Th1 and Treg cells (P > 0.05). Plasma concentrations of IL-17A, IL-4, and IL-6 in patients with HSP were found to be much higher than those of the control group (P < 0.05), and no differences between IFN-γ, IL-12, and TGF-β were detected between the two groups (P > 0.05). Presence of higher proportions of Th2 and Th17 cells in patients with HSP could be closely correlated with aberrant creation of antibody and development of vessel vasculitis. The changes in cytokine milieu in peripheral blood may play an important role in the derangement of CD4+ T cell subset.
Literatur
1.
Zurück zum Zitat Reamy BV, Williams PM, Lindsay TJ (2009) Henoch-Schönlein purpura. Am Fam Physician 80:697–704PubMed Reamy BV, Williams PM, Lindsay TJ (2009) Henoch-Schönlein purpura. Am Fam Physician 80:697–704PubMed
2.
Zurück zum Zitat Yang YH, Chuang YH, Wang LC, Huang HY, Gershwin ME, Chiang BL (2008) The immunobiology of Henoch-Schönlein purpura. Autoimmun Rev 7:179–184PubMedCrossRef Yang YH, Chuang YH, Wang LC, Huang HY, Gershwin ME, Chiang BL (2008) The immunobiology of Henoch-Schönlein purpura. Autoimmun Rev 7:179–184PubMedCrossRef
3.
Zurück zum Zitat Namgoong MK, Lim BK, Kim JS (1997) Eosinophil cationic protein in Henoch-Schönlein purpura and in IgA nephropathy. Pediatr Nephrol 11:703–706PubMedCrossRef Namgoong MK, Lim BK, Kim JS (1997) Eosinophil cationic protein in Henoch-Schönlein purpura and in IgA nephropathy. Pediatr Nephrol 11:703–706PubMedCrossRef
4.
Zurück zum Zitat Del Vecchio GC, Penza R, Altomare M, Piacente L, Aceto G, Lassandro G, De Mattia D, Giordano P (2008) Cytokine pattern and endothelium damage markers in Henoch-Schönlein purpura. Immunopharmacol Immunotoxicol 30:623–629PubMedCrossRef Del Vecchio GC, Penza R, Altomare M, Piacente L, Aceto G, Lassandro G, De Mattia D, Giordano P (2008) Cytokine pattern and endothelium damage markers in Henoch-Schönlein purpura. Immunopharmacol Immunotoxicol 30:623–629PubMedCrossRef
5.
Zurück zum Zitat Davin JC, Pierard G, Dechenne C, Grossman D, Nagy J, Quacoe M, Malaise M, Hall M, Jansen F, Chantraine JM (1994) Possible pathogenic role of IgE in Henoch-Schönlein purpura. Pediatr Nephrol 8:169–171PubMedCrossRef Davin JC, Pierard G, Dechenne C, Grossman D, Nagy J, Quacoe M, Malaise M, Hall M, Jansen F, Chantraine JM (1994) Possible pathogenic role of IgE in Henoch-Schönlein purpura. Pediatr Nephrol 8:169–171PubMedCrossRef
6.
Zurück zum Zitat Nakayama T, Yamashita M (2008) Initiation and maintenance of Th2 cell identity. Curr Opin Immunol 20:265–271PubMedCrossRef Nakayama T, Yamashita M (2008) Initiation and maintenance of Th2 cell identity. Curr Opin Immunol 20:265–271PubMedCrossRef
7.
Zurück zum Zitat Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 31:787–793CrossRef Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 31:787–793CrossRef
8.
Zurück zum Zitat Hudak SA, Gollnick SO, Conrad DH, Kehry MR (1987) Murine B-cell stimulatory factor 1 (interleukin 4) increases expression of the Fc receptor for IgE on mouse B cells. Proc Natl Acad Sci USA 84:4606–4610PubMedCrossRef Hudak SA, Gollnick SO, Conrad DH, Kehry MR (1987) Murine B-cell stimulatory factor 1 (interleukin 4) increases expression of the Fc receptor for IgE on mouse B cells. Proc Natl Acad Sci USA 84:4606–4610PubMedCrossRef
9.
Zurück zum Zitat Fang SP, Tanaka T, Tago F, Okamoto T, Kojima S (2005) Immunomodulatory effects of gyokuheifusan on INF-gamma/IL-4 (Th1/Th2) balance in ovalbumin (OVA)-induced asthma model mice. Biol Pharm Bull 28:829–833PubMedCrossRef Fang SP, Tanaka T, Tago F, Okamoto T, Kojima S (2005) Immunomodulatory effects of gyokuheifusan on INF-gamma/IL-4 (Th1/Th2) balance in ovalbumin (OVA)-induced asthma model mice. Biol Pharm Bull 28:829–833PubMedCrossRef
10.
Zurück zum Zitat Grünig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB (1998) Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261–2263PubMedCrossRef Grünig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB (1998) Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261–2263PubMedCrossRef
12.
Zurück zum Zitat Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA (1999) IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 162:920–930PubMed Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA (1999) IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 162:920–930PubMed
13.
Zurück zum Zitat Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, de Waal Malefyt R, de Vries JE (1993) Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 90(8):3730–3734PubMedCrossRef Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, de Waal Malefyt R, de Vries JE (1993) Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 90(8):3730–3734PubMedCrossRef
14.
Zurück zum Zitat Kawasaki Y, Hosoya M, Suzuki H (2005) Possible pathologenic role of interleukin-5 and eosino cationic protein in Henoch-Schönlein purpura nephritis. Pediatr Int 47:512–517PubMedCrossRef Kawasaki Y, Hosoya M, Suzuki H (2005) Possible pathologenic role of interleukin-5 and eosino cationic protein in Henoch-Schönlein purpura nephritis. Pediatr Int 47:512–517PubMedCrossRef
15.
Zurück zum Zitat Chintalacharuvu SR, Emancipator SN (1997) The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. J Immunol 159:2327–2333PubMed Chintalacharuvu SR, Emancipator SN (1997) The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. J Immunol 159:2327–2333PubMed
16.
Zurück zum Zitat Koutkia P, Mylonakis E, Rounds S, Erickson A (2001) Leucocytoclastic vasculitis: an update for the clinician. Scand J Rheumatol 30:315–322PubMedCrossRef Koutkia P, Mylonakis E, Rounds S, Erickson A (2001) Leucocytoclastic vasculitis: an update for the clinician. Scand J Rheumatol 30:315–322PubMedCrossRef
18.
Zurück zum Zitat Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240PubMedCrossRef Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233–240PubMedCrossRef
19.
Zurück zum Zitat Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls J, van den Berg WB (2002) Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 51:102–104PubMedCrossRef Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls J, van den Berg WB (2002) Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 51:102–104PubMedCrossRef
20.
Zurück zum Zitat Lindén A, Hoshino H, Laan M (2000) Airway neutrophils and interleukin-17. Eur Respir J 15:973–977PubMedCrossRef Lindén A, Hoshino H, Laan M (2000) Airway neutrophils and interleukin-17. Eur Respir J 15:973–977PubMedCrossRef
21.
Zurück zum Zitat Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H (1999) Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5:101–104PubMed Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H (1999) Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5:101–104PubMed
22.
Zurück zum Zitat Kolls JK, Lindén A (2004) Interleukin-17 family members and inflammation. Immunity 21:467–476PubMedCrossRef Kolls JK, Lindén A (2004) Interleukin-17 family members and inflammation. Immunity 21:467–476PubMedCrossRef
23.
Zurück zum Zitat Besbas N, Saatci U, Ruacan S, Ozen S, Sungur A, Bakkaloglu A, Elnahas AM (1997) The role of cytokines in Henoch Schonlein purpura. Scand J Rheumatol 26:456–460PubMedCrossRef Besbas N, Saatci U, Ruacan S, Ozen S, Sungur A, Bakkaloglu A, Elnahas AM (1997) The role of cytokines in Henoch Schonlein purpura. Scand J Rheumatol 26:456–460PubMedCrossRef
24.
Zurück zum Zitat Yang YH, Wang SJ, Chuang YH, Lin YT, Chiang BL (2002) The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch-Schönlein purpura. Clin Exp Immunol 130:352–357PubMedCrossRef Yang YH, Wang SJ, Chuang YH, Lin YT, Chiang BL (2002) The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch-Schönlein purpura. Clin Exp Immunol 130:352–357PubMedCrossRef
25.
Zurück zum Zitat Yang YH, Lai HJ, Huang CM, Wang LC, Lin YT, Chiang BL (2004) Sera from children with active Henoch-Schönlein purpura can enhance the production of interleukin 8 by human umbilical venous endothelial cells. Ann Rheum Dis 63:1511–1513PubMedCrossRef Yang YH, Lai HJ, Huang CM, Wang LC, Lin YT, Chiang BL (2004) Sera from children with active Henoch-Schönlein purpura can enhance the production of interleukin 8 by human umbilical venous endothelial cells. Ann Rheum Dis 63:1511–1513PubMedCrossRef
26.
Zurück zum Zitat Wang LJ, Yang YH, Lin YT, Chiang BL (2006) Levels of intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 in children with Henoch-Schönlein purpura. J Microbiol Immunol Infect 39:109–113PubMed Wang LJ, Yang YH, Lin YT, Chiang BL (2006) Levels of intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 in children with Henoch-Schönlein purpura. J Microbiol Immunol Infect 39:109–113PubMed
27.
Zurück zum Zitat Gok F, Ugur Y, Ozen S, Dagdeviren A (2008) Pathogenesis-related adhesion molecules in Henoch-Schonlein vasculitis. Rheumatol Int 28:313–316PubMedCrossRef Gok F, Ugur Y, Ozen S, Dagdeviren A (2008) Pathogenesis-related adhesion molecules in Henoch-Schonlein vasculitis. Rheumatol Int 28:313–316PubMedCrossRef
28.
Zurück zum Zitat Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238PubMedCrossRef Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238PubMedCrossRef
29.
Zurück zum Zitat Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345–350PubMedCrossRef Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345–350PubMedCrossRef
Metadaten
Titel
Investigation of the change in CD4+ T cell subset in children with Henoch–Schonlein purpura
verfasst von
Yuan-yuan Li
Cheng-rong Li
Guo-bing Wang
Jun Yang
Ying Zu
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 12/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2266-3

Weitere Artikel der Ausgabe 12/2012

Rheumatology International 12/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.